Related Experiment Video
Updated: Aug 24, 2026

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
Proteomic approaches in cancer risk and response assessment
Emanuel F Petricoin1, Lance A Liotta
1FDA-NCI, Clinical Proteomics Program, Building 29A, Room 2D12, 8800 Rockville Pike, Bethesda, MD 20892, USA. petricoin@cber.fda.gov
Abstract:
Proteomics is more than just a list-generating exercise where increases or decreases in protein expression are identified. Proteomic technologies will ultimately characterize information-flow through the protein circuitry that interconnects the extracellular microenvironment to the serum or plasma macroenvironment through intracellular signaling systems and their control of gene transcription. The nature of this information can be a cause or a consequence of disease processes and how patients respond to therapy. Analysis of human cancer as a model for how proteomics can have an impact at the bedside can take advantage of several promising new proteomic technologies. These technologies are being developed for early detection and risk assessment, therapeutic targeting and patient-tailored therapy.
More Related Videos
Related Concept Videos
Proteomics
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Pharmacogenomics: Identification of New Drug Targets

